cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Apellis Pharmaceuticals Inc
17 own
17 watching
Current Price
$47.5
$-0.53
(-1.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,582.34M
52-Week High
52-Week High
94.75000
52-Week Low
52-Week Low
19.83000
Average Volume
Average Volume
0.95M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization7,582.34M
icon52-Week High94.75000
icon52-Week Low19.83000
iconAverage Volume0.95M
iconDividend Yield--
iconP/E Ratio--
What does the Apellis Pharmaceuticals Inc do?
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More
How much money does Apellis Pharmaceuticals Inc make?
News & Events about Apellis Pharmaceuticals Inc.
PR Newswire
11 months ago
Thinking about trading options or stock in BILL Holdings, Apellis Pharmaceuticals, Apple, Boeing, or General Electric? Thinking about trading options or stock in BILL Holdings, Apellis Pharmaceuticals, Apple, Boeing, or General Electric? PR Newswire NEW YORK, May 5, 2023 NEW YORK, May 5, 2023...
Zolmax
12 months ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) Director Alec Machiels sold 1,250 shares of the stock in a transaction dated Monday, April 17th. The stock was sold at an average price of $81.05, for a total transaction of $101,312.50. Following the completion of the sale, the director now ...
Globe Newswire
12 months ago
Applications are under review in Canada, Australia, the United Kingdom, and SwitzerlandApproval decisions expected in the first half of 2024 WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, ...
Ticker Report
12 months ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) Director Alec Machiels sold 1,250 shares of the businesss stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $81.05, for a total value of $101,312.50. Following the completion ...
Ticker Report
1 year ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS Get Rating) insider Pascal Deschatelets sold 12,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 10th. The stock was sold at an average price of $78.21, for a total transaction of $938,520.00. Following the sale, the ...
Frequently Asked Questions
Frequently Asked Questions
What is Apellis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Apellis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Apellis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Apellis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Apellis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Apellis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Apellis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Apellis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Apellis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Apellis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$47.5
$-0.53
(-1.1%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00